PMID- 26444967
OWN - NLM
STAT- MEDLINE
DCOM- 20161215
LR  - 20161230
IS  - 1421-9832 (Electronic)
IS  - 1018-8665 (Linking)
VI  - 232
IP  - 1
DP  - 2016
TI  - Are Anti-TNF-alpha Agents Safe for Treating Psoriasis in Hepatitis C Virus Patients 
      with Advanced Liver Disease? Case Reports and Review of the Literature.
PG  - 102-6
LID - 10.1159/000439587 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) inhibitors represent an effective treatment 
      for severe psoriasis in hepatitis C virus (HCV) patients. The literature reports 
      mainly on short-term treatment in patients with chronic hepatitis with 
      minimum-to-moderate activity with an acceptable safety profile. We report the 
      first 2 cases of hepatocellular carcinoma (HCC) arising in HCV psoriatic patients 
      with advanced liver disease during long-term treatment with etanercept. Our first 
      patient, known to have had HCV infection for 41 years, developed an HCC after 21 
      months of therapy with etanercept (50 mg/week). The second patient, HCV+ for 20 
      years, was treated for 58 months with the same therapy, and despite no signs of 
      liver function impairment was diagnosed with HCC. Both of them presented with 
      cirrhosis, which was diagnosed 9 and 5 years earlier, respectively. It remains to 
      be clarified whether there is any connection between psoriasis treatment with 
      anti-TNF-alpha agents and the development of HCC in HCV-infected patients. Further 
      long-term, follow-up studies and registries of HCV patients with mild/moderate 
      activity may contribute to clarify this issue.
CI  - (c) 2015 S. Karger AG, Basel.
FAU - Di Nuzzo, Sergio
AU  - Di Nuzzo S
AD  - Section of Dermatology, Department of Clinical and Experimental Medicine, 
      University of Parma, Parma, Italy.
FAU - Boccaletti, Valeria
AU  - Boccaletti V
FAU - Fantini, Carolina
AU  - Fantini C
FAU - Cortelazzi, Chiara
AU  - Cortelazzi C
FAU - Missale, Gabriele
AU  - Missale G
FAU - Fabrizi, Giuseppe
AU  - Fabrizi G
FAU - Lotti, Torello
AU  - Lotti T
FAU - Hercogova, Jana
AU  - Hercogova J
FAU - Pagliarello, Calogero
AU  - Pagliarello C
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20151008
PL  - Switzerland
TA  - Dermatology
JT  - Dermatology (Basel, Switzerland)
JID - 9203244
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Carcinoma, Hepatocellular/etiology
MH  - Etanercept/*adverse effects
MH  - Hepatitis C, Chronic/*complications
MH  - Humans
MH  - Immunosuppressive Agents/*adverse effects
MH  - Liver Neoplasms/etiology
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/complications/*drug therapy/virology
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2015/10/08 06:00
MHDA- 2016/12/16 06:00
CRDT- 2015/10/08 06:00
PHST- 2015/03/26 00:00 [received]
PHST- 2015/08/20 00:00 [accepted]
PHST- 2015/10/08 06:00 [entrez]
PHST- 2015/10/08 06:00 [pubmed]
PHST- 2016/12/16 06:00 [medline]
AID - 000439587 [pii]
AID - 10.1159/000439587 [doi]
PST - ppublish
SO  - Dermatology. 2016;232(1):102-6. doi: 10.1159/000439587. Epub 2015 Oct 8.